MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study. (October 2022) - Ou, S.H.; Moreno Garcia, V.; Gil Bazo, I.; Prenen, H.; Moreno, I.; Johnson, M.; Castañón Álvarez, E.; Nagasaka, M.; Adeyemi, S.; Barasa, B.; Bol, K.; Doze, P.; et al.